J
JN Atkins
Publications - 9
Citations - 3654
JN Atkins is an academic researcher. The author has contributed to research in topics: Breast cancer & Docetaxel. The author has an hindex of 5, co-authored 9 publications receiving 3443 citations.
Papers
More filters
Journal ArticleDOI
The Influence of Finasteride on the Development of Prostate Cancer
Ian M. Thompson,Phyllis J. Goodman,Catherine M. Tangen,M. Scott Lucia,Gary J. Miller,Leslie G. Ford,Michael M. Lieber,R. Duane Cespedes,JN Atkins,Scott M. Lippman,Susie M. Carlin,Anne Ryan,Connie M. Szczepanek,John Crowley,Charles A. Coltman +14 more
TL;DR: Finasteride prevents or delays the appearance of prostate cancer, but this possible benefit and a reduced risk of urinary problems must be weighed against sexual side effects and the increased risk of high-grade prostate cancer.
Journal ArticleDOI
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
Joseph A. Sparano,Robert Gray,D. F. Makower,Kathleen I. Pritchard,Kathy S. Albain,Daniel F. Hayes,Charles E. Geyer,Elizabeth Claire Dees,E. A. Perez,John A. Olson,John A. Olson,J. A. Zujewski,J. A. Zujewski,Tracy Lively,Sunil Badve,Tom Saphner,Lynne I. Wagner,Timothy J. Whelan,Matthew J. Ellis,Matthew J. Ellis,Soonmyung Paik,Soonmyung Paik,William C. Wood,Peter M. Ravdin,M. Keane,H. L. Gomez Moreno,Pavan S. Reddy,Timothy F. Goggins,Ingrid A. Mayer,Adam Brufsky,Deborah Toppmeyer,Virginia G. Kaklamani,JN Atkins,Jeffrey L. Berenberg,George W. Sledge,George W. Sledge +35 more
TL;DR: In this article, a prospective trial involving women with hormone-receptor-positive, human epidermal growth factor receptor type 2 (HER2)-negative, axillary node-negative breast cancer with tumors of 1.1 to 5.0 cm in the greatest dimension (or 0.6 to 1.0cm in the intermediate or high tumor grade) who met established guidelines for the consideration of adjuvant chemotherapy on the basis of clinicopathologic features.
Proceedings ArticleDOI
Abstract GS1-02: NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC)
Louis Fehrenbacher,Reena S. Cecchini,Charles E. Geyer,P Rastogi,Joseph P. Costantino,JN Atkins,Jonathan Polikoff,J-F Boileau,Louise Provencher,C Stokoe,TD Moore,André Robidoux,Virginia F. Borges,KS Albain,Sandra M. Swain,Soonmyung Paik,Eleftherios P. Mamounas,Norman Wolmark +17 more
TL;DR: In this paper, the authors showed that the addition of trastuzumab (H) to CT did not demonstrate a reduction in IDFS, RFI, or DRFI in women with non-overexpressing but IHC measurable HER2 IBC.
Proceedings ArticleDOI
NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer.
Sandra M. Swain,J-H Jeong,Charles E. Geyer,Joseph P. Costantino,ER Pajon,Louis Fehrenbacher,JN Atkins,Jonathan Polikoff,Victor G. Vogel,John K. Erban,Robert B. Livingston,E. A. Perez,Eleftherios P. Mamounas,Patricia A. Ganz,Stephanie R. Land,Norman Wolmark +15 more
TL;DR: The presentation will include the first results of DFS, OS, and relevant toxicities from the trial, as well as a comparison of toxicities among the three regimens.
Proceedings ArticleDOI
PD07-08: The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy: NSABP Protocol B-40.
Harry D. Bear,Gong Tang,Priya Rastogi,Charles E. Geyer,R André,JN Atkins,Luis Baez-Diaz,Adam Brufsky,Rita S. Mehta,Louis Fehrenbacher,ER Pajon,Francis M. Senecal,Rakesh Gaur,Richard G. Margolese,Paul T. Adams,Howard M. Gross,Joseph P. Costantino,Sandra M. Swain,Eleftherios P. Mamounas,Norman Wolmark +19 more
TL;DR: The NSABP trial B-40 was designed to determine whether adding capecitabine or gem citabine to docetaxel followed by AC would increase the pathologic complete response (pCR) rates in patients with operable HER2−negative breast cancer and whether the addition of bevacizumab to three docetAXel-based regimens followed byAC would increase pCR rates.